These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparison of the virologic and immunologic responses of volunteers to live avian-human influenza A H3N2 reassortant virus vaccines derived from two different avian influenza virus donors. Clements ML; Sears SD; Christina K; Murphy BR; Snyder MH J Clin Microbiol; 1989 Jan; 27(1):219-22. PubMed ID: 2913033 [TBL] [Abstract][Full Text] [Related]
10. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Clements ML; O'Donnell S; Levine MM; Chanock RM; Murphy BR Infect Immun; 1983 Jun; 40(3):1044-51. PubMed ID: 6852910 [TBL] [Abstract][Full Text] [Related]
11. [Antibody formation and preservation against the envelope antigens of influenza virus subtype A(H3N2) after infection and vaccination]. Stumpa A; Tůmová B Tr Inst Im Pastera; 1982; 59():23-8. PubMed ID: 6764986 [No Abstract] [Full Text] [Related]
12. Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers. Clements ML; Snyder MH; Buckler-White AJ; Tierney EL; London WT; Murphy BR J Clin Microbiol; 1986 Jul; 24(1):47-51. PubMed ID: 3722365 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the antineuraminidase antibody response to vaccination with intact virus and subunit preparations obtained by different techniques of the influenza virus strains A/Sing/1/57 (H2N2), A/Hong Kong/1/68 (H3N2) and A/Port Chalmers/1/73 (H3N2). Drescher J; Desselberger U Comp Immunol Microbiol Infect Dis; 1980; 3(1-2):219-23. PubMed ID: 6162604 [No Abstract] [Full Text] [Related]
14. Immunogenicity of inactivated influenza vaccine containing A/Niigata/102/81 (H3N2). Increase of HAI antibodies to different variants of the subtype. Takeuchi Y; Takahashi M; Satsuta K; Hatta S; Suzuki H; Ogawa Y; Hirano S; Takahashi K; Yamazi Y Nihon Ika Daigaku Zasshi; 1985 Oct; 52(5):607-10. PubMed ID: 4066903 [No Abstract] [Full Text] [Related]
15. Peculiarities of obtaining attenuated thermosensitive recombinants of influenza A virus at the end of the H3N2 epidemic cycle. Polezhaev FI; Garmashova LM; Rumovsky VI; Aleksandrova GI; Smorodintsev AA Acta Virol; 1980 Jun; 24(4):273-8. PubMed ID: 6106378 [TBL] [Abstract][Full Text] [Related]
16. Antibody responses to inactivated influenza vaccines and partial protective effect of anti-neuraminidase antibody against epidemics of A(H3N2) and A(H1N1) influenza. Maeda A; Oishi I; Minekawa Y; Kunita N; Funahashi S; Yagura H Biken J; 1979 Sep; 22(3):91-8. PubMed ID: 533537 [No Abstract] [Full Text] [Related]
17. Morphology and antigenicity studies on reassortant influenza (H3N2) viruses for use in inactivated vaccines. Pemberton RM; Jennings R; Smith TL J Hyg (Lond); 1985 Apr; 94(2):229-39. PubMed ID: 2580887 [TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Hrabar A; Vodopija I; André FE; Mitchell JR; Maassab HF; Hennessy AV; Davenport FM Dev Biol Stand; 1977 Jun 1-3; 39():53-60. PubMed ID: 342317 [No Abstract] [Full Text] [Related]
19. Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. Mortiz AJ; Kunz C; Hofman H; Liehl E; Reeve P; Maassab HF J Infect Dis; 1980 Dec; 142(6):857-60. PubMed ID: 7462697 [TBL] [Abstract][Full Text] [Related]